Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments
With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion’s mission is transformational. We seek to combine product technologies with novel targeting strategies to support our ultimate goal of improving survival and providing cures for challenging cancers. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is our lead product candidate. ThermoDox is currently being evaluated in the OPTIMA Study, a global phase 3 clinical trial for the treatment of primary liver cancer, and in the EU-DIGNITY Study, a phase 2 clinical trial for the treatment of recurrent chest wall breast cancer (RCW). Next in our pipeline is GEN-1, a highly promising treatment that incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in the phase 1 OVATION Study, in combination with chemotherapy, for newly diagnosed ovarian cancer patients.